PIK3CB and cancer: Although pan‐PI3K inhibitors are emerging as a new opportunity in the treatment of non‐cancer‐related diseases, data derived from clinical trials has demonstrated that treatment with pan‐PI3K inhibitors causes several side effects, including nausea, diarrhea, rash, and increased released of insulin in plasma.